Loading...
Loading...
RAIN| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 20.4M |
| Operating I/L | -23.2M |
| Other Income/Expense | -2.8M |
| Interest Income | 1.2M |
| Pretax | -22.1M |
| Income Tax Expense | 1.7M |
| Net Income/Loss | -22.1M |
Rain Therapeutics Inc. is a clinical-stage precision oncology company focused on developing therapies targeting oncogenic drivers. Its lead product candidate, milademetan, is a small molecule oral inhibitor of mouse double minute 2, being evaluated in Phase 3 and Phase II clinical trials for various cancers, including liposarcoma, solid tumors, and intimal sarcoma. The company is also developing RAD52, a potential treatment for breast, ovarian, pancreatic, prostate, and other tumors. Rain Therapeutics Inc. generates revenue through the development and potential commercialization of its precision oncology therapies.
